Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression
- Authors
- Park, Chul-Kee; Kim, Jin Hyun; Moon, Min Jeong; Jung, Ji Hye; Lim, Su-Young; Park, Sung-Hye; Kim, Jong-Hoon; Kim, Dong Gyu; Jung, Hee-Won; Cho, Byung-Kyu; Paek, Sun Ha
- Issue Date
- 2월-2008
- Publisher
- SPRINGER
- Keywords
- mass spectrometry; oligodendroglioma; malignant transformation; peroxiredoxin; rho GDP dissociation inhibitor
- Citation
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v.134, no.2, pp.255 - 262
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Volume
- 134
- Number
- 2
- Start Page
- 255
- End Page
- 262
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/124126
- DOI
- 10.1007/s00432-007-0282-1
- ISSN
- 0171-5216
- Abstract
- Purpose Frozen tumor tissues from a patient who showed rapid progression to anaplastic oligodendroglioma after near total resection of oligodendroglioma were used to examine differential expression of proteins to gain better understanding of the pathogenesis of malignant transformation. Methods We have determined their protein profiles using a 2D gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry approach. Results Among 23 differentially expressed spots, overexpression of peroxiredoxin 6 and underexpression of rho GDP dissociation inhibitor alpha were confirmed to be valid after western blot and immunocytochemical analysis of oligodendroglioma tissue. Conclusions Abnormal expression of peroxiredoxin 6 and rho GDP dissociation inhibitor alpha may be associated with malignant transformation in oligodendroglioma and these proteins might be candidates of molecular predictive factors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biotechnology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.